搜索结果
ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
---|
化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
---|
TCMBANKIN003665 | evoden | C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O | |||
TCMBANKIN016585 | P-dichlorobenzene | C6H4Cl2 | 147 g/mol | C1=CC(=CC=C1Cl)Cl | |
TCMBANKIN016952 | vitamin d | (6R)-6-[(1R,3aS,4E,7aR)-4-{2-[(1Z,5R)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene}-7a-methyl-octahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol; CHEBI:89324; 24,25-dihydroxyvitamin; 24,25-Dihydroxyvitamin D; 24,25-Dihydroxycholecalciferol; 24,25-dihydroxyvitamin D3; (3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol | C27H44O3 | 416.6 g/mol | CC(CCC(C(C)(C)O)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C |
TCMBANKIN027899 | Succinate | C4H4O4-2 | 116.07 g/mol | C(CC(=O)[O-])C(=O)[O-] | |
TCMBANKIN029777 | vitamin d3 | C28H46O | 398.7 g/mol | CC(C)C(C)CCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C | |
TCMBANKIN030237 | androgen | C22H32O3 | 344.5 g/mol | CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C | |
TCMBANKIN037514 | Lawsonin | 174.15 g/mol | |||
TCMBANKIN040323 | Auxin A | 328.4 g/mol | |||
TCMBANKIN047407 | Bilobalide A | 326.3 | |||
TCMBANKIN057905 | ferrum | iron | Fe | 55.84 g/mol | [Fe] |
TCMBANKIN057906 | mercury | hydrargyrum | Hg | 200.59 g/mol | [Hg] |
TCMBANKIN058052 | diAllS2 | 3-prop-2-enyldisulfanylprop-1-ene; NSC 29228; Di(2-propenyl) disulfide; W202800_ALDRICH; Allyl disulphide; 3,3'-dithiobis(prop-1-ene); NCI60_002410; ZINC01531082; AI3-35128; SPECTRUM1505174; HSDB 595; 3-(prop-2-en-1-yldisulfanyl)prop-1-ene; 2179-57-9; Allyl disulfide; AIDS-005092; BRN 1699241; Diallyl disulphide; NCGC00095294-01; NSC29228; CHEBI:4488; Disulfide, di-2-propenyl; AIDS005092; C08369; 317691_ALDRICH; 3-allyldisulfanylprop-1-ene; 2-Propenyl disulfide; 3,3'-disulfanediylbis(prop-1-ene); 3-(allyldisulfanyl)-1-propene; 4,5-Dithia-1,7-octadiene; 4-01-00-02098 (Beilstein Handbook Reference); FEMA No. 2028; NCGC00095294-02; EINECS 218-548-6; 32621_FLUKA; CCRIS 6290; Diallyl disulfide; 2-Propenyl disulphide;allyl disulfide;diallyldisulfide;CAS-2179-57-9; DSSTox_RID_79248; CCG-214421; NCI60_002410; C-27435; Jsp004430; AI3-35128; HSDB 595; di-Propenyl disulfide; Allyl disulfide; 3-(prop-2-en-1-yldisulfanyl)prop-1-ene; SPECTRUM1505174; ZINC1531082; LS-16413; NCGC00095294-01; DTXSID9035206; TC-040016; UNII-609MRV3T0J component PFRGXCVKLLPLIP-UHFFFAOYSA-N; CHEBI:4488; SCHEMBL93944; MolPort-003-665-653; SR-05000002379; MFCD00008656; Garlicin?; DSSTox_CID_15206; CJ-24085; NSC-29228; Disulfide,di-2-propenyl; TRA0072391; FCH1114751; 2-Propenyl disulphide; Di(2-propenyl) disulfide; 3-(Allyldisulfanyl)-1-propene; 3-Allyldisulfanyl-Propene; Allyl disulfide, United States Pharmacopeia (USP) Reference Standard; AN-20744; FEMA 2028; diAllS2; CTK3J1568; CHEMBL366603; J-014293; Allitin; ACMC-1CDL1; Allyl disulfide, >=80%, FG; BDBM50318453; AC1L28A0; Disulfide, di-2-propen-1-yl; 1,2-Diallyldisulfane; A815665; FEMA No. 2028; 7491AF; NCGC00095294-02; API0002303; AKOS015840490; AK307043; ANW-24581; 3-(prop-2-enyldisulfanyl)prop-1-ene; 5HI47O6OA7; NSC 29228; DB-003623; Allyl disulphide; diprop-2-enyl disulfide; CJ-05228; 3,3'-dithiobis(prop-1-ene); Allyl disulfide, technical grade, 80%; DIALLYL DISULFIDE; 2179-57-9; Diallyldisulfide; ST51038174; KS-00000V5X; 3-(Allyldisulfanyl)-1-propene #; Diallyl disulfide, analytical standard; C6H10S2; 2-Propenyl disulfide; 4,5-Dithia-1,7-octadiene; D0071; EINECS 218-548-6; Diallyl disulfide, >=98% (HPLC); CCRIS 6290; PFRGXCVKLLPLIP-UHFFFAOYSA-N; Tox21_302178; MCULE-7486690483; UNII-5HI47O6OA7; 3-(allyldisulfanyl)prop-1-ene; Di-2-propenyl disulfide, 9CI; I09-0165; RTC-040016; KSC491K6R; NCGC00255533-01; BRN 1699241; Diallyl disulphide; NSC29228; DSSTox_GSID_35206; Disulfide, di-2-propenyl; CC-26440; C08369; 3,3'-disulfanediylbis(prop-1-ene); SC-77190; di-2-Propenyl disulfide; diallyldisulphide; 3-(prop-2-enyldisulfanyl)-1-propene; AC1Q7EA7; FT-0624594; SR-05000002379-1;diallyl disulfide ; diallyl disulfide | C6H10S2 | 146.27 | C=CCSSCC=C |
TCMBANKIN058374 | Indolyl acetic acid | 3-indolylaceticacid;Indole acetic acid;IES;heteroauxin;1H-Indole-3-acetic acid (9CI); beta-Indoleacetic acid; 54692-39-6; I8262_SIGMA; CHEBI:16411; 87-51-4; 1H-indol-3-ylacetic acid; CCRIS 1014; Heteroauxin; InChI=1/C10H9NO2/c12-10(13)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H,12,13; 1H-Indole-3-acetic-a-t acid (9CI); EPA Pesticide Chemical Code 128915; EU-0099905; Indole-3-acetic acid-carboxy-14C; Acetic acid, indolyl-; beta-Indolylacetic acid; I3750_ALDRICH; omega-Skatole carboxylic acid; 2-(1H-Indol-3-yl)acetic acid; .beta.-Indole-3-acetic acid; MLS001066408; I2886_SIGMA; C00954; Hexteroauxin; .beta.-Indolylacetic acid; Indol-3-ylacetic acid; Rhizopin; Indole-3-acetic acid (8CI); [3H]-IAA; NSC 3787; Indole-3-acetic-t acid; WLN: T56 BMJ D1VQ; 3-(Carboxymethyl)indole; .alpha.-Indol-3-yl-acetic acid; 45533_RIEDEL; (1H-Indol-3-yl)acetic acid; ST5308201; .omega.-Skatole carboxylic acid; Maybridge1_006755; IAA; SDCCGMLS-0066204.P001; beta-IAA; Indoleacetic acid (VAN); 3-IAA; 3-Indolylacetic acid; 6305-45-9; Indolyl-3-acetic acid; 3-Indolylessigsaeure; Oprea1_602123; indole-3-acetic acid; IAC; Rhizopon A; Kyselina 3-indolyloctova [Czech]; 2-(3-Indolyl)acetic acid 3-(Carboxymethyl)-1H-indole; 1H-Indole-3-acetic acid; 3-Indolylmethylcarboxylic acid; .beta.-IAA; AIDS009893; SMR000471855; SR-01000596909-2; EINECS 201-748-2; 2-(1H-indol-3-yl)ethanoic acid; alpha-IAA; Heteroauxinhexteroauxiniaa; .alpha.-IAA; indoleacetic acid; 2-(indol-3-yl)ethanoic acid; 3-Indoleacetic acid; NSC3787; .beta.-Indoleacetic acid; AIDS-009893; AI3-24131 | C10H9NO2 | 175.18 g/mol | C1=CC=C2C(=C1)C(=CN2)CC(=O)O |
TCMBANKIN058990 | forskolin | coleonol | C22H34O7 | 410.5 g/mol | CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O |
TCMBANKIN059532 | (1R)-1, 7, 7-trimethyl-bicyclo[2.2.1]heptan-2-one | C10H16O | 152.23 g/mol | CC1(C2CCC1(C(=O)C2)C)C | |
TCMBANKIN059716 | 4-(2,6,6- trimethyl- 1- cyclohexen- 1- yl)- 3-buten-2- one | C13H20O | 192.3 g/mol | CC1=C(C(CCC1)(C)C)C=CC(=O)C | |
TCMBANKIN060110 | oestrone | C18H22O2 | 270.4 g/mol | CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O | |
TCMBANKIN060111 | 17alpha-estradiol | C18H24O2 | 272.4 g/mol | CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O | |
TCMBANKIN060811 | Di(2-ethylhexyl)phthalate;Ethylhexyl phthalate;phthalic acid bis-(2-ethyl-hexyl)ester;bis(2-ethyl-hexyl)-phthalate;Octoil | C24H38O4 | 390.6 g/mol | CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC | |
TCMBANKIN060910 | cis-9-hexadecenoic acid | C16H30O2 | 254.41 g/mol | CCCCCCC=CCCCCCCCC(=O)O | |
TCMBANKIN061003 | Dodekan,dodecane,n-dodecane | C12H26 | 170.33 g/mol | CCCCCCCCCCCC | |
TCMBANKIN061038 | Gaidic acid | C16H30O2 | 254.41 g/mol | CCCCCCCCCCCCCC=CC(=O)O |
疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
---|
TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI000035 | Digestive System Diseases; Infections | - | Disease or Syndrome | disease | |
TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
TCMBANKDI000088 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | group | |
TCMBANKDI000092 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | disease | |
TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
TCMBANKDI000296 | Eye Diseases | Abnormality of the immune system; Abnormality of the eye | Disease or Syndrome | disease | |
TCMBANKDI000771 | Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of the immune system | Sign or Symptom | phenotype | |
TCMBANKDI002512 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
TCMBANKDI002891 | - | Abnormality of limbs; Abnormality of the skeletal system | Finding | phenotype | |
TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
TCMBANKDI004145 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | group | |
TCMBANKDI005757 | Endocrine System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI006230 | - | Abnormality of the skeletal system | Finding | phenotype | |
TCMBANKDI007110 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
TCMBANKDI008641 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Female Urogenital Diseases and Pregnancy Complications; Musculoskeletal Diseases; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI009080 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of head or neck | Disease or Syndrome | disease | |
TCMBANKDI009572 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | phenotype | |
TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
TCMBANKDI010160 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
TCMBANKDI011174 | Infections | - | Disease or Syndrome | group | |
TCMBANKDI011557 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
TCMBANKDI011982 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
TCMBANKDI012744 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Female Urogenital Diseases and Pregnancy Complications; Musculoskeletal Diseases; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI012976 | Neoplasms; Stomatognathic Diseases | - | Neoplastic Process | disease | |
TCMBANKDI013986 | - | Abnormality of the skeletal system | Finding | phenotype | |
TCMBANKDI014531 | Pathological Conditions, Signs and Symptoms; Neoplasms; Musculoskeletal Diseases | - | Neoplastic Process | disease | |
TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI018567 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI018680 | Eye Diseases; Immune System Diseases; Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
TCMBANKDI019962 | Infections; Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
TCMBANKDI020119 | Mental Disorders | Abnormality of the nervous system | Finding | phenotype | |
TCMBANKDI020603 | Pathological Conditions, Signs and Symptoms | - | Anatomical Abnormality | phenotype | |
TCMBANKDI020912 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI021076 | Musculoskeletal Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI021387 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | phenotype | |
TCMBANKDI021622 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
TCMBANKDI022111 | - | Abnormality of limbs; Abnormality of the skeletal system | Finding | phenotype | |
TCMBANKDI022565 | - | - | Finding | phenotype | |
TCMBANKDI022910 | Female Urogenital Diseases and Pregnancy Complications; Infections; Male Urogenital Diseases | - | Disease or Syndrome | group | |
TCMBANKDI023498 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
TCMBANKDI024159 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Sign or Symptom | phenotype | |
TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
TCMBANKDI025141 | Endocrine System Diseases | Abnormality of the endocrine system; Abnormality of the immune system | Disease or Syndrome | disease | |
TCMBANKDI025732 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI026626 | - | Abnormality of the endocrine system | Finding | phenotype | |
TCMBANKDI029220 | Nutritional and Metabolic Diseases; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
TCMBANKDI029713 | - | Abnormality of head or neck; Abnormality of the skeletal system | Finding | phenotype | |
TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
TCMBANKDI032419 | - | Growth abnormality | Finding | phenotype |